ACADIA Pharmaceuticals (ACAD) News Today $19.13 -0.47 (-2.40%) Closing price 02/6/2025 04:00 PM EasternExtended Trading$19.05 -0.08 (-0.44%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period High Growth Tech Stocks To Watch In February 2025February 6 at 10:51 PM | finance.yahoo.comMorgan Stanley Remains a Hold on ACADIA Pharmaceuticals (ACAD)February 6 at 10:51 PM | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Rezolute (RZLT) and Pfizer (PFE)February 4 at 12:15 PM | markets.businessinsider.comLeerink Partnrs Issues Optimistic Forecast for ACAD EarningsFebruary 2, 2025 | americanbankingnews.comShort Interest in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Grows By 14.5%February 1, 2025 | americanbankingnews.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Short Interest UpdateACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 10,720,000 shares, an increase of 14.5% from the December 31st total of 9,360,000 shares. Based on an average daily trading volume, of 2,230,000 shares, the days-to-cover ratio is presently 4.8 days.February 1, 2025 | marketbeat.comOptimistic Buy Rating for ACADIA Pharmaceuticals Driven by Patient Growth and Strategic MarketingJanuary 31, 2025 | markets.businessinsider.comFY2024 Earnings Forecast for ACAD Issued By Leerink PartnrsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Leerink Partnrs lifted their FY2024 earnings estimates for ACADIA Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical coJanuary 31, 2025 | marketbeat.comLeerink Partnrs Has Optimistic Outlook of ACAD Q4 EarningsJanuary 31, 2025 | americanbankingnews.comACADIA Pharmaceuticals' SWOT analysis: stock outlook amid mixed product performanceJanuary 30, 2025 | msn.comLeerink Partnrs Has Bullish Forecast for ACAD Q4 EarningsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Leerink Partnrs boosted their Q4 2024 EPS estimates for shares of ACADIA Pharmaceuticals in a note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the biopharmaceutical company will postJanuary 30, 2025 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Average Rating of "Moderate Buy" by AnalystsShares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) have received an average rating of "Moderate Buy" from the seventeen analysts that are currently covering the company, MarketBeat.com reports. Seven analysts have rated the stock with a hold recommendation and ten have issued aJanuary 27, 2025 | marketbeat.comBrokers Issue Forecasts for ACAD FY2025 EarningsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of ACADIA Pharmaceuticals in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipatesJanuary 24, 2025 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Up 6.4% - Still a Buy?ACADIA Pharmaceuticals (NASDAQ:ACAD) Trading Up 6.4% - Here's What HappenedJanuary 23, 2025 | marketbeat.comCantor Fitzgerald Forecasts ACAD FY2025 EarningsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for ACADIA Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan forecasts that the bioJanuary 23, 2025 | marketbeat.comSG Americas Securities LLC Raises Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)SG Americas Securities LLC increased its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 380.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,483,731 shares of the biopharmaceutical company's stock afterJanuary 23, 2025 | marketbeat.comTD Cowen Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)January 22, 2025 | markets.businessinsider.comPacira BioSciences Strengthens Executive Leadership Team with Two Key AppointmentsJanuary 21, 2025 | finance.yahoo.comAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 17, 2025 | businesswire.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Sees Large Growth in Short InterestACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 10,720,000 shares, an increase of 14.5% from the December 15th total of 9,360,000 shares. Based on an average daily volume of 2,230,000 shares, the days-to-cover ratio is presently 4.8 days.January 17, 2025 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Down 6.9% - Time to Sell?ACADIA Pharmaceuticals (NASDAQ:ACAD) Trading Down 6.9% - Should You Sell?January 16, 2025 | marketbeat.comBurney Co. Purchases Shares of 378,903 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Burney Co. purchased a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 378,903 shares of the biopharmaceutical company's stock,January 15, 2025 | marketbeat.comAcadia submits MAA to EMA for Rett syndrome therapyJanuary 15, 2025 | finance.yahoo.comAcadia Pharma Submits MAA To EU Agency For Approval Of Trofinetide In Rett SyndromeJanuary 15, 2025 | markets.businessinsider.comHealth Check: Biotech partnership eyes Euro market expansion for Rett syndrome drugJanuary 14, 2025 | msn.comACADIA Pharmaceuticals: Strong Growth Prospects and Strategic Expansions Justify Buy RatingJanuary 14, 2025 | markets.businessinsider.comAcadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025January 14, 2025 | finance.yahoo.comWhy did this $1.4 billion ASX 200 healthcare stock just dive 9%?January 14, 2025 | msn.comAcadia Pharmaceuticals: Positive Sales Projections Amidst Pipeline UncertaintyJanuary 14, 2025 | markets.businessinsider.comACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Down 6.9% - Should You Sell?ACADIA Pharmaceuticals (NASDAQ:ACAD) Trading Down 6.9% - What's Next?January 14, 2025 | marketbeat.comIs ACADIA Pharmaceuticals (ACAD) the Best Medical Stock to Buy Under $20?January 12, 2025 | insidermonkey.comACADIA Pharmaceuticals (ACAD) Receives a Buy from RBC CapitalJanuary 11, 2025 | markets.businessinsider.comGuggenheim downgrades Acadia Pharmaceuticals to Neutral on lack of catalystsJanuary 4, 2025 | markets.businessinsider.comGuggenheim Downgrades ACADIA Pharmaceuticals (ACAD)January 4, 2025 | msn.comPrincipal Financial Group Inc. Increases Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Principal Financial Group Inc. lifted its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 67.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 129,551 sharJanuary 4, 2025 | marketbeat.comAcadia Pharmaceuticals downgraded to Neutral from Buy at GuggenheimJanuary 3, 2025 | msn.comACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap Down - Here's WhyACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap Down - Time to Sell?January 3, 2025 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Downgraded to Neutral Rating by GuggenheimGuggenheim downgraded shares of ACADIA Pharmaceuticals from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $23.00 to $20.00 in a research report on Friday.January 3, 2025 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Sees Large Volume Increase - What's Next?ACADIA Pharmaceuticals (NASDAQ:ACAD) Sees Large Volume Increase - Here's WhyJanuary 2, 2025 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from AnalystsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) has received an average rating of "Moderate Buy" from the sixteen ratings firms that are currently covering the company, MarketBeat Ratings reports. Six investment analysts have rated the stock with a hold rating and ten have given a buy rJanuary 2, 2025 | marketbeat.comAcadia Pharmaceuticals Shares Rise With Co to Join S&P SmallCap 600December 31, 2024 | marketwatch.comACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap Up - Here's What HappenedACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap Up - Still a Buy?December 31, 2024 | marketbeat.comShort Interest in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Decreases By 5.5%ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totalling 9,360,000 shares, a drop of 5.5% from the November 30th total of 9,910,000 shares. Based on an average daily volume of 1,530,000 shares, the days-to-cover ratio is currently 6.1 days.December 31, 2024 | marketbeat.com3 Specialty Pharma Stocks Addressing Unmet Medical NeedsDecember 24, 2024 | stocknews.comGeode Capital Management LLC Acquires 30,826 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Geode Capital Management LLC raised its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 1.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 2,875,540 shares of the biopharmaceutical company's stock after acquiring an additiDecember 24, 2024 | marketbeat.comBarclays PLC Raises Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Barclays PLC lifted its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 126.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 277,565 shares of the biopharmaceutical company's stock after purcDecember 22, 2024 | marketbeat.comAcadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025December 19, 2024 | businesswire.comACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Down 2.9% - What's Next?ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Down 2.9% - Should You Sell?December 19, 2024 | marketbeat.comState Street Corp Purchases 173,084 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)State Street Corp grew its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 3.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,973,874 shares of the biophaDecember 17, 2024 | marketbeat.comAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 16, 2024 | businesswire.com Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Media Mentions By Week ACAD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACAD News Sentiment▼0.780.50▲Average Medical News Sentiment ACAD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACAD Articles This Week▼148▲ACAD Articles Average Week Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dr. Reddy's Laboratories News Sarepta Therapeutics News Vaxcyte News Qiagen News Roivant Sciences News Ascendis Pharma A/S News Revolution Medicines News Blueprint Medicines News Legend Biotech News Lantheus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACAD) was last updated on 2/7/2025 by MarketBeat.com Staff From Our PartnersNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThis Crypto Is Set to Explode in JanuaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredDeepSeek Just Awoke a Sleeping GiantEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free Acad Stock Alerts